NASDAQ:MIST - CA59935V1076 - Common Stock
The current stock price of MIST is 1.84 USD. In the past month the price increased by 28.67%. In the past year, price increased by 29.58%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 45.36 | 693.36B | ||
JNJ | JOHNSON & JOHNSON | 17.72 | 426.69B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.44 | 250.88B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.73B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.3 | 244.98B | ||
MRK | MERCK & CO. INC. | 10.92 | 210.11B | ||
PFE | PFIZER INC | 7.3 | 140.77B | ||
SNY | SANOFI-ADR | 11.17 | 120.68B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.03B | ||
GSK | GSK PLC-SPON ADR | 8.76 | 79.97B | ||
ZTS | ZOETIS INC | 25.14 | 69.31B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.97 | 47.34B |
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
MILESTONE PHARMACEUTICALS IN
420-1111 boul. Dr.-Frederik-Philips
MONTREAL QUEBEC H4M 2X6 CA
CEO: Joseph Oliveto
Employees: 33
Phone: 15143360444
The current stock price of MIST is 1.84 USD. The price increased by 1.66% in the last trading session.
The exchange symbol of MILESTONE PHARMACEUTICALS IN is MIST and it is listed on the Nasdaq exchange.
MIST stock is listed on the Nasdaq exchange.
10 analysts have analysed MIST and the average price target is 3.4 USD. This implies a price increase of 84.78% is expected in the next year compared to the current price of 1.84. Check the MILESTONE PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MILESTONE PHARMACEUTICALS IN (MIST) has a market capitalization of 156.38M USD. This makes MIST a Micro Cap stock.
MILESTONE PHARMACEUTICALS IN (MIST) currently has 33 employees.
MILESTONE PHARMACEUTICALS IN (MIST) has a support level at 1.75 and a resistance level at 1.85. Check the full technical report for a detailed analysis of MIST support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MIST does not pay a dividend.
MILESTONE PHARMACEUTICALS IN (MIST) will report earnings on 2025-11-10, before the market open.
MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
The outstanding short interest for MILESTONE PHARMACEUTICALS IN (MIST) is 6.9% of its float. Check the ownership tab for more information on the MIST short interest.
ChartMill assigns a technical rating of 8 / 10 to MIST. When comparing the yearly performance of all stocks, MIST is one of the better performing stocks in the market, outperforming 81.52% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to MIST. MIST has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 16.76% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -117.11% | ||
ROE | N/A | ||
Debt/Equity | N/A |
10 analysts have analysed MIST and the average price target is 3.4 USD. This implies a price increase of 84.78% is expected in the next year compared to the current price of 1.84.